Phathom Pharmaceuticals, Inc. filings document financial reporting, governance, capital structure and product-development disclosures for a Nasdaq-listed biopharmaceutical company focused on gastrointestinal diseases. Form 8-K reports include quarterly and annual results, preliminary financial information, material agreements, financing-related updates, and other event disclosures tied to VOQUEZNA® commercialization and clinical development.
Proxy materials cover board matters, executive compensation, equity awards and shareholder voting items. The filing record also describes registered common stock, risk-oriented forward-looking statements, and clinical or publication updates involving VOQUEZNA in GERD, non-erosive reflux disease and eosinophilic esophagitis.
Phathom Pharmaceuticals is launching an underwritten public offering of common stock and pre-funded warrants. Certain investors can buy pre-funded warrants instead of shares, each with a $0.001 per-share exercise price and a 19.99% ownership cap to limit concentration. The company plans to use the net proceeds for general corporate purposes, including working capital plus commercialization and research and development spending.
Phathom reports that VOQUEZNA products have surpassed one million prescriptions dispensed in the United States since launch, highlighting growing GI franchise usage. Based on current plans, it anticipates achieving operating profitability in the second half of 2026, excluding stock-based compensation. New buyers face immediate dilution because the offering price will be above the company’s negative net tangible book value as of September 30, 2025.
Phathom Pharmaceuticals, Inc. filed a current report to disclose that it has issued a press release with certain preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. The company states that this press release, dated January 7, 2026, is included as an exhibit and incorporated by reference into its securities law filings, making the early 2025 figures part of its official disclosure record.
Phathom Pharmaceuticals has registered 5,827,415 shares of common stock for potential resale by a large stockholder, with all sale proceeds going to that holder rather than the company.
Separately, as a well-known seasoned issuer, Phathom has filed an automatic shelf registration on Form S-3 that allows it to offer common stock, preferred stock, debt securities, warrants and units from time to time, with specific terms and uses of proceeds to be detailed in future prospectus supplements.
The company focuses on gastrointestinal treatments built around vonoprazan, the active ingredient in its VOQUEZNA-branded products for conditions such as erosive GERD and H. pylori infection.
Phathom Pharmaceuticals, Inc. reported an equity award transaction for its President, CEO and Director, Steven L. Basta. On January 2, 2026, he received 251,034 restricted stock units (RSUs) of common stock at a price of $0 per share, increasing his directly held common stock to 364,820 shares after the transaction. Each RSU represents a right to receive one share of common stock.
The RSUs vest over three years, with one-third of the award vesting on each of the first three anniversaries of January 2, 2026, subject to his continued service. On the same date, he was also granted a stock option to purchase 226,156 shares of common stock at an exercise price of $15.71 per share, expiring on January 1, 2036. One forty-eighth of the option vests monthly following the vesting commencement date, conditioned on his continuous service.
Phathom Pharmaceuticals, Inc. President and CEO Steven L. Basta exercised 90,000 performance stock units, receiving an equal number of common shares on November 28, 2025. In connection with this vesting, 48,375 shares were delivered to the issuer at $15.62 per share to satisfy tax withholding obligations. After these transactions, he held 83,250 shares of common stock directly. A grant on April 3, 2025 covered 360,000 performance stock units, of which 90,000 vested on September 25, 2025 and another 90,000 on November 28, 2025; remaining units vest upon achievement of stock price hurdles over four years.
Phathom Pharmaceuticals (PHAT) insider filing: The company’s Principal Accounting Officer reported a sale of common stock on 11/03/2025. The filing shows 524 shares sold at $13.51 (transaction code S).
The footnote states the shares were sold to satisfy tax withholding obligations upon the settlement of restricted stock units. Following the transaction, beneficial ownership stands at 47,407 shares held directly and 6,945.4 shares held indirectly via a 401(k).
Phathom Pharmaceuticals announced the first patient has been dosed in its Phase 2 pHalcon EoE-201 trial evaluating VOQUEZNA (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis in adults.
The study is a two-part, randomized, double-blind, placebo-controlled trial. Part 1 will enroll 80 adults with endoscopic-confirmed EoE and dysphagia, randomized to VOQUEZNA 20 mg or placebo once daily for 12 weeks. Patients who complete Part 1 may enter a 12-week extension (Part 2), where all participants receive VOQUEZNA 20 mg.
Topline primary and secondary results are anticipated in 2027. The company also noted typical development uncertainties and forward-looking risks related to study conduct, enrollment, outcomes, and future program decisions.
Phathom Pharmaceuticals (PHAT) reported Q3 2025 results with product revenue of $49.5 million, up from $16.4 million a year ago as VOQUEZNA sales expanded. Gross profit reached $43.3 million and operating loss narrowed to $15.3 million. Net loss was $30.0 million, or $0.41 per share, versus $85.6 million, or $1.32 per share, last year.
For the first nine months, product revenue totaled $117.5 million versus $25.6 million in 2024, and net loss improved to $200.1 million from $259.9 million. Cash and cash equivalents were $135.2 million, with stockholders’ deficit at $422.5 million. Long‑term debt, net, was $207.1 million, and the revenue interest financing liability stood at $373.3 million (including $24.3 million current). The company recorded $9.2 million of restructuring charges in May to streamline operations.
Management states it has sufficient working capital for at least the next twelve months. An at‑the‑market program for up to $150 million remains unused. Shares outstanding were 71,138,440 as of October 27, 2025.
Phathom Pharmaceuticals furnished a press release announcing financial results for the quarter ended September 30, 2025. The release was provided as Exhibit 99.1 to an Item 2.02 report.
Under General Instruction B.2, the information in the report, including Exhibit 99.1, is treated as furnished and not filed.
Phathom Pharmaceuticals (PHAT) reported that additional analyses from its pivotal Phase 3 pHalcon-NERD-301 trial of VOQUEZNA (vonoprazan) in Non-Erosive Reflux Disease were published in the American Journal of Gastroenterology. The article, “Vonoprazan Improves Nocturnal Gastroesophageal Reflux Symptoms in Non-Erosive Reflux Disease,” highlights the burden of nighttime GERD symptoms.
In the trial, 772 patients were randomized to VOQUEZNA 10 mg, 20 mg, or placebo for 4 weeks, followed by a 20-week extension with active treatment. Nighttime GERD symptoms affect up to an estimated 80% of patients and are linked to impaired sleep and productivity. The company also included standard forward-looking statement cautions about clinical performance and market acceptance.